Biotechnology

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

As RESTEM presents at BIO 2026, the company showcases its novel cell therapies aiming to reprogram the immune system, not just manage symptoms.

Model N's acquisition of Kalderos targets the chaotic 340B drug discount program, a system where 99% of pharma leaders lack real-time data visibility.

With $4.3M in seed funding and a roster of industry titans, Acurion is poised to commercialize its OncoGaze™ AI, aiming to make precision oncology faster.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

With an oversubscribed $7.2M Series A, Icarus Medical is leveraging 3D printing and novel biomechanics to redefine treatment for millions with knee pain.

With a novel FDA clearance for its at-home UVB device, Solius Labs isn't just launching a product; it's creating a new market for personalized medicine.

A landmark victory at the 2026 Autoflower World Cup validates 42 Fast Buds' strategic pivot to in-house cultivation, setting a new benchmark for the industry.

A groundbreaking partnership turns millions of registered organ donors into potential living kidney donors, tackling a waitlist of 90,000 with one simple step.

Chronic fatigue, anxiety, and burnout are surging. A new wave of data-driven, integrative medicine claims to have the answer, moving beyond symptoms to the root cause.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new partnership between Medventions and Mitacs aims to fix Canada's innovation gap by embedding engineers directly into clinics. Here's how it works.

A new partnership aims to replace needles with pills for a powerful class of drugs, using advanced AI to solve a multi-billion dollar challenge in medicine.

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

As federal support for science wanes, the National Cancer Center adds top minds from Stanford and Harvard to identify and fund the next wave of cancer cures.

An Israeli biotech just published a patent for a 'mucoadhesive' gel that makes drugs stick inside the nose. It's a key step in a multi-billion dollar race.

A key update to a revolutionary cancer therapy reduces post-treatment restrictions, signaling a new era of patient-centric care and system efficiency in Canada.

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

The communications firm adds three seasoned experts, a strategic move to guide biotech and pharma clients through increasingly volatile capital markets.